24 week treatment of former relapse, HCV genotype 1 infected patients with telaprevir in combination with peginterferon alfa 2a/ribavirin – experiences under real life conditions, Boeker et al. . . . vorgestellt anlässlich des Liver Meeting of the American Association for the Study of Liver Diseases 2013 (AASLD) in Washington, DC, (USA).
